EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma

Layla Ahmadi, Malak Khalifeh, Dimitar Donovski, DuyKhanh Pham Ceppa, Patrick Loehrer, Rohan Maniar, Huda Salman

Proceedings of IMPRS · 30.03.2026 · 8 (1)

DOI: 10.18060/29592 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of IMPRS, online erschienen am 30.03.2026. Verfasst von Layla Ahmadi und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thymic carcinomas are rare anterior mediastinal malignancies with limited treatment options and modest responses to platinum-based chemotherapy. Immune checkpoint inhibitors have shown activity but often cause severe immune-related toxicities. Although CAR T-cell therapy has revolutionized hematologic cancer treatment, its application in thymic carcinoma is limited due to disease rarity, lack of tumor-specific surface antigens, and risks of on-target off-tumor toxicity, especially given the thymus’s role in immune tolerance. Recent studies have identified overexpression of TROP-2, c-KIT, and CD70 in thymic carcinoma, presenting novel therapeutic targets.

Objectives

Profile TROP-2, c-KIT, and CD70 surface expression on thymic carcinoma–relevant cell lines. Engineer CAR constructs targeting each antigen and validate CAR expression on T- cells. Evaluate antigen-specific cytotoxicity of CAR T-Cells in vitro to guide development of multi-antigen CAR T strategies.

Methods

Candidate cell lines were screened for surface expression of TROP-2, c-KIT, and CD70 using quantitative flow cytometry. CAR T-cells were generated from healthy donor PBMCs via lentiviral transduction and expanded ex vivo. Antigen-specific cytotoxicity was evaluated through in vitro coculture assays using selected patient-derived cell lines. Cytotoxic effects were quantified by 7-AAD via flow cytometry.

Results

Flow cytometry confirmed high surface expression of TROP-2 (83%), c-KIT (88%), and CD70 (99%) in T1889, Kasumi, and U266 cell lines, respectively. Lentiviral transduction produced Fab⁺ CAR-T populations of 48.2% (TROP-2), 24.7% (c-KIT), and 47.5% (CD70). All three CAR-T constructs showed antigen-specific cytotoxicity significantly greater than GFP⁺ CD3⁺ controls.

Conclusions

This study provides early in vitro evidence supporting CAR T-cell therapy targeting TROP-2, c- KIT, and CD70 for thymic carcinoma. Results confirm strong CAR expression and potent, selective killing of antigen-positive targets.

Zitieren

APA

Ahmadi, L., Khalifeh, M., Donovski, D., Ceppa, D. P., Loehrer, P., Maniar, R., & Salman, H. (2026). Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma. Proceedings of IMPRS, 8(1). https://doi.org/10.18060/29592

Vancouver

Ahmadi L, Khalifeh M, Donovski D, Ceppa DP, Loehrer P, Maniar R, et al. Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma. Proceedings of IMPRS. 2026;8(1). doi:10.18060/29592

BibTeX
@article{Ahmadi2026,
  author = {Ahmadi, Layla and Khalifeh, Malak and Donovski, Dimitar and Ceppa, DuyKhanh Pham and Loehrer, Patrick and Maniar, Rohan and Salman, Huda},
  title = {Development of a Novel CAR T-Cell Therapy Targeting Thymic Carcinoma},
  journal = {Proceedings of IMPRS},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.18060/29592}
}
Kostenlos starten →